India  

Zydus' Virafin gets emergency use approval for treating moderate COVID-19 cases

Video Credit: ANI - Duration: 02:01s - Published
Zydus' Virafin gets emergency use approval for treating moderate COVID-19 cases

Zydus' Virafin gets emergency use approval for treating moderate COVID-19 cases

The Drugs Controller General of India (DGCI) has approved emergency use for Zydus Cadila's Pegylated Interferon alpha-2b, 'Virafin' for treating moderate COVID-19 infection in adults.

A release by Cadila Health said, "The drug has also shown efficacy against other viral infections."Speaking on the development, Dr Sharvil Patel, Managing Director, Cadila Healthcare Limited said: "The fact that we are able to offer a therapy which significantly reduces viral load when given early on can help in better disease management.

It comes at a much-needed time for patients and we will continue to provide them access to critical therapies in this battle against COVID-19." This government's approval for use of the antiviral drug comes at a time when India's daily COVID tally is crossing the 3-lakh mark.

India recorded 3,32,730 new COVID-19 cases in the last 24 hours, the highest single-day spike since the pandemic broke out last year.

India has crossed the mark of 3 lakh COVID-19 cases for two consecutive days now.

This has taken the cumulative count of the COVID infection in the country to 1,62,63,695.


You Might Like


๐Ÿ’ก newsR Knowledge: Other News Mentions

COVID-19 COVID-19 Contagious disease caused by SARS-CoV-2

Cure or Threat? Wuhan Lab's New Intranasal Vaccine Sparks Fears of Another Covid-like Crisis [Video]

Cure or Threat? Wuhan Lab's New Intranasal Vaccine Sparks Fears of Another Covid-like Crisis

A new intranasal vaccine developed by researchers at the Wuhan lab has recently been unveiled, promising a novel approach to combating infectious diseases. However, this breakthrough has also sparked significant controversy and concern. While the vaccineโ€™s potential to offer a more accessible and efficient method of vaccination is hailed as a major advancement, its origins and the circumstances surrounding its development are raising alarms about a possible new health crisis. Critics worry that the technology used in this vaccine could inadvertently lead to another pandemic-like scenario if not carefully monitored. As the world cautiously watches, the vaccine's rollout is stirring a heated debate about safety, preparedness, and the ethical implications of such advanced biological research. #IntranasalVaccine #WuhanLab #CovidCrisis #HealthFears #VaccineDebate #PandemicRisk #BioResearch #VaccineDevelopment #PublicHealth #InfectiousDiseases #SafetyConcerns #GlobalHealth #VaccineInnovation #EthicalIssues #HealthSecurity ~HT.97~PR.152~

Credit: Oneindia    Duration: 03:29Published

Related videos from verified sources

What is Virafin? How does the Zydus Cadila drug work? | Oneindia News [Video]

What is Virafin? How does the Zydus Cadila drug work? | Oneindia News

Zydus Cadila's Virafin has been approved for emergency use to treat moderate Covid-19 patients by the drug controller general of india. How does Virafin work? #Virafin #ZydusCadila #CovidDrug

Credit: Oneindia     Duration: 01:24Published
Covid-19: Centre to fast-track emergency approval for vaccines| Oneindia News [Video]

Covid-19: Centre to fast-track emergency approval for vaccines| Oneindia News

The Centre has decided to fast-track emergency approval for COVID-19 vaccines uses in western nations and Japan after the world's biggest surge in cases in the country this month. In view of the rising..

Credit: Oneindia     Duration: 02:13Published
Vaccinations for 12 to 15-year-olds could be available in weeks [Video]

Vaccinations for 12 to 15-year-olds could be available in weeks

Local medical experts believe now that Pfizer has applied for Emergency Use Authorization for their COVID vaccine for those 12-15, that age group could be eligible for a vaccine by the end of the..

Credit: KMTV Action 3 News     Duration: 03:08Published